Clinical Trial Update: Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating an immunochemotherapy approach with surgery or chemoradiation followed by durvalumab for stage IIIA/B non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: University Hospital, Bonn | Conditions: Lung Cancer Non-Small Cell Cancer (NSCLC) | Phase 2 | Status: RECRUITING